Radiotherapy from within The Bone For Patients with Metastatic Castration‐Resistant Prostate Cancer (mCRPC)

索引

00:00 1.
Radiotherapy from within The Bone For Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
00:17 2.
Goals of treatment for mCRPC
00:38 3.
Frequency and Impact of Skeletal Involvement among Patients with Advanced Cancer
00:50 4.
Slide 4
01:32 5.
Slide 5
01:45 6.
Slide 6
02:08 7.
Slide 7
02:24 8.
Slide 8
02:56 9.
Slide 9
03:15 10.
Slide 10
03:42 11.
Slide 11
04:13 12.
Strontium 89 acts as a calcium mimic targets bone metastases
04:43 13.
First use of strontium-89
04:48 14.
Strontium revisited
04:54 15.
Slide 8
05:05 16.
Slide 13
05:11 17.
Slide 14
05:38 18.
Radium-223
05:56 19.
Phase I biodistribution study of Radium-223
06:24 20.
Radium-223 Dichloride Solution for Injection
06:51 21.
Why Alpha?
07:47 22.
Slide 25
08:08 23.
ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) Phase III Study Design
08:46 24.
Bq V.S Ci
09:11 25.
ALSYMPCA Study Endpoints
09:32 26.
ALSYMPCA OS Analyses
10:01 27.
ALSYMPCA Overall Survival
10:19 28.
ALSYMPCA Time to First Skeletal-Related Event
10:32 29.
ALSYMPCA OS Analyses
10:35 30.
ALSYMPCA Updated AnalysisPatient Demographics and Baseline Characteristics (ITT N = 921)
10:48 31.
ALSYMPCA Updated AnalysisPatient Baseline Characteristics (ITT N = 921)
11:03 32.
ALSYMPCA Updated AnalysisPatient Disposition
11:17 33.
Slide 33
11:32 34.
Slide 34
12:08 35.
Slide 35
12:21 36.
Slide 36
12:59 37.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:21 38.
Slide 38
13:26 39.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:32 40.
Slide 38
13:46 41.
Slide 39
14:16 42.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
14:49 43.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
15:14 44.
Relative Risk Of Individual Symptomatic Skeletal Event components
15:24 45.
ZA delayed first SRE in bone metastatic CRPC
15:30 46.
Denosumab vs. ZA: time to first on-study SRE
15:35 47.
ALSYMPCA Updated AnalysisSecondary Endpoints: ALP and PSA
16:16 48.
Slide 46
16:29 49.
Slide 47
16:35 50.
Ra-223 early access program (EAP)
17:30 51.
ALSYMPCA Updated AnalysisAEs of Interest
18:08 52.
Safety of Cytotoxic Chemotherapy Following Rd-223 Therapy
18:54 53.
1.5-Year Posttreatment Follow-up of Radium-223 Dichloride (Radium-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study
19:04 54.
ALSYMPCA Long-term Follow-Up
19:06 55.
Conclusions
19:41 56.
Optimal timing of ra-223
20:31 57.
Optimal timing of ra-223
21:03 58.
ALSYMPCA AP in Taiwan
21:11 59.
Slide 57
21:13 60.
PSA response
22:23 61.
ALP / BPI Change
22:31 62.
ALP / BPI Change
22:31 63.
ALSYMPCA: ALP Response and Normalization
22:53 64.
Slide 62
23:22 65.
Dose Escalating Phase I study
23:31 66.
Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting. 2014 ASCO Annual MeetingCitation: J Clin Oncol 32, 2014 (suppl; abstr e16106)
23:51 67.
Slide 65
24:01 68.
Adverse Events
24:13 69.
Introduction
24:38 70.
Radium-223 Dichloride Solution for Injection
24:48 71.
Dose of Radium-223 Compared with Common Radiopharmaceuticals
24:59 72.
Pharmacy and Administration of Radium-223
25:21 73.
ALYSMPCA Updated Analysis Conclusions
25:37 74.
ALYSMPCA Updated Analysis Conclusions
25:45 75.
Ra-223 ongoing studies with combination regimen
26:28 76.
Ongoing trial in Taiwan
27:13 77.
Thanks For Your Attention

筆記 (0)

未登入或權限不足!

討論

00:00 1.
Radiotherapy from within The Bone For Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
00:17 2.
Goals of treatment for mCRPC
00:38 3.
Frequency and Impact of Skeletal Involvement among Patients with Advanced Cancer
00:50 4.
Slide 4
01:32 5.
Slide 5
01:45 6.
Slide 6
02:08 7.
Slide 7
02:24 8.
Slide 8
02:56 9.
Slide 9
03:15 10.
Slide 10
03:42 11.
Slide 11
04:13 12.
Strontium 89 acts as a calcium mimic targets bone metastases
04:43 13.
First use of strontium-89
04:48 14.
Strontium revisited
04:54 15.
Slide 8
05:05 16.
Slide 13
05:11 17.
Slide 14
05:38 18.
Radium-223
05:56 19.
Phase I biodistribution study of Radium-223
06:24 20.
Radium-223 Dichloride Solution for Injection
06:51 21.
Why Alpha?
07:47 22.
Slide 25
08:08 23.
ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) Phase III Study Design
08:46 24.
Bq V.S Ci
09:11 25.
ALSYMPCA Study Endpoints
09:32 26.
ALSYMPCA OS Analyses
10:01 27.
ALSYMPCA Overall Survival
10:19 28.
ALSYMPCA Time to First Skeletal-Related Event
10:32 29.
ALSYMPCA OS Analyses
10:35 30.
ALSYMPCA Updated AnalysisPatient Demographics and Baseline Characteristics (ITT N = 921)
10:48 31.
ALSYMPCA Updated AnalysisPatient Baseline Characteristics (ITT N = 921)
11:03 32.
ALSYMPCA Updated AnalysisPatient Disposition
11:17 33.
Slide 33
11:32 34.
Slide 34
12:08 35.
Slide 35
12:21 36.
Slide 36
12:59 37.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:21 38.
Slide 38
13:26 39.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:32 40.
Slide 38
13:46 41.
Slide 39
14:16 42.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
14:49 43.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
15:14 44.
Relative Risk Of Individual Symptomatic Skeletal Event components
15:24 45.
ZA delayed first SRE in bone metastatic CRPC
15:30 46.
Denosumab vs. ZA: time to first on-study SRE
15:35 47.
ALSYMPCA Updated AnalysisSecondary Endpoints: ALP and PSA
16:16 48.
Slide 46
16:29 49.
Slide 47
16:35 50.
Ra-223 early access program (EAP)
17:30 51.
ALSYMPCA Updated AnalysisAEs of Interest
18:08 52.
Safety of Cytotoxic Chemotherapy Following Rd-223 Therapy
18:54 53.
1.5-Year Posttreatment Follow-up of Radium-223 Dichloride (Radium-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study
19:04 54.
ALSYMPCA Long-term Follow-Up
19:06 55.
Conclusions
19:41 56.
Optimal timing of ra-223
20:31 57.
Optimal timing of ra-223
21:03 58.
ALSYMPCA AP in Taiwan
21:11 59.
Slide 57
21:13 60.
PSA response
22:23 61.
ALP / BPI Change
22:31 62.
ALP / BPI Change
22:31 63.
ALSYMPCA: ALP Response and Normalization
22:53 64.
Slide 62
23:22 65.
Dose Escalating Phase I study
23:31 66.
Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting. 2014 ASCO Annual MeetingCitation: J Clin Oncol 32, 2014 (suppl; abstr e16106)
23:51 67.
Slide 65
24:01 68.
Adverse Events
24:13 69.
Introduction
24:38 70.
Radium-223 Dichloride Solution for Injection
24:48 71.
Dose of Radium-223 Compared with Common Radiopharmaceuticals
24:59 72.
Pharmacy and Administration of Radium-223
25:21 73.
ALYSMPCA Updated Analysis Conclusions
25:37 74.
ALYSMPCA Updated Analysis Conclusions
25:45 75.
Ra-223 ongoing studies with combination regimen
26:28 76.
Ongoing trial in Taiwan
27:13 77.
Thanks For Your Attention

分享
- Facebook
- Twitter
- LinkedIn
- 嵌入網址
- QR code

索引
筆記
討論
全螢幕

Radiotherapy from within The Bone For Patients with Metastatic Castration‐Resistant Prostate Cancer (mCRPC)

長度: 27:24, 瀏覽: 843, 最近修訂: 2017-05-19

00:00 1.
Radiotherapy from within The Bone For Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
00:17 2.
Goals of treatment for mCRPC
00:38 3.
Frequency and Impact of Skeletal Involvement among Patients with Advanced Cancer
00:50 4.
Slide 4
01:32 5.
Slide 5
01:45 6.
Slide 6
02:08 7.
Slide 7
02:24 8.
Slide 8
02:56 9.
Slide 9
03:15 10.
Slide 10
03:42 11.
Slide 11
04:13 12.
Strontium 89 acts as a calcium mimic targets bone metastases
04:43 13.
First use of strontium-89
04:48 14.
Strontium revisited
04:54 15.
Slide 8
05:05 16.
Slide 13
05:11 17.
Slide 14
05:38 18.
Radium-223
05:56 19.
Phase I biodistribution study of Radium-223
06:24 20.
Radium-223 Dichloride Solution for Injection
06:51 21.
Why Alpha?
07:47 22.
Slide 25
08:08 23.
ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) Phase III Study Design
08:46 24.
Bq V.S Ci
09:11 25.
ALSYMPCA Study Endpoints
09:32 26.
ALSYMPCA OS Analyses
10:01 27.
ALSYMPCA Overall Survival
10:19 28.
ALSYMPCA Time to First Skeletal-Related Event
10:32 29.
ALSYMPCA OS Analyses
10:35 30.
ALSYMPCA Updated AnalysisPatient Demographics and Baseline Characteristics (ITT N = 921)
10:48 31.
ALSYMPCA Updated AnalysisPatient Baseline Characteristics (ITT N = 921)
11:03 32.
ALSYMPCA Updated AnalysisPatient Disposition
11:17 33.
Slide 33
11:32 34.
Slide 34
12:08 35.
Slide 35
12:21 36.
Slide 36
12:59 37.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:21 38.
Slide 38
13:26 39.
ALSYMPCA Updated Analysis: Radium-223 Improved OS Across All Patient Subgroups
13:32 40.
Slide 38
13:46 41.
Slide 39
14:16 42.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
14:49 43.
Time to 1st Symptomatic Skeletal Event, By Baseline Stratification Factors
15:14 44.
Relative Risk Of Individual Symptomatic Skeletal Event components
15:24 45.
ZA delayed first SRE in bone metastatic CRPC
15:30 46.
Denosumab vs. ZA: time to first on-study SRE
15:35 47.
ALSYMPCA Updated AnalysisSecondary Endpoints: ALP and PSA
16:16 48.
Slide 46
16:29 49.
Slide 47
16:35 50.
Ra-223 early access program (EAP)
17:30 51.
ALSYMPCA Updated AnalysisAEs of Interest
18:08 52.
Safety of Cytotoxic Chemotherapy Following Rd-223 Therapy
18:54 53.
1.5-Year Posttreatment Follow-up of Radium-223 Dichloride (Radium-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study
19:04 54.
ALSYMPCA Long-term Follow-Up
19:06 55.
Conclusions
19:41 56.
Optimal timing of ra-223
20:31 57.
Optimal timing of ra-223
21:03 58.
ALSYMPCA AP in Taiwan
21:11 59.
Slide 57
21:13 60.
PSA response
22:23 61.
ALP / BPI Change
22:31 62.
ALP / BPI Change
22:31 63.
ALSYMPCA: ALP Response and Normalization
22:53 64.
Slide 62
23:22 65.
Dose Escalating Phase I study
23:31 66.
Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting. 2014 ASCO Annual MeetingCitation: J Clin Oncol 32, 2014 (suppl; abstr e16106)
23:51 67.
Slide 65
24:01 68.
Adverse Events
24:13 69.
Introduction
24:38 70.
Radium-223 Dichloride Solution for Injection
24:48 71.
Dose of Radium-223 Compared with Common Radiopharmaceuticals
24:59 72.
Pharmacy and Administration of Radium-223
25:21 73.
ALYSMPCA Updated Analysis Conclusions
25:37 74.
ALYSMPCA Updated Analysis Conclusions
25:45 75.
Ra-223 ongoing studies with combination regimen
26:28 76.
Ongoing trial in Taiwan
27:13 77.
Thanks For Your Attention

位置

資料夾名稱

2015臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2017-05-19 17:04:06

最近修訂

2017-05-19 19:23:18

長度

27:24